Table 3. Univariate/multivariate analysis of prognostic factors for progression free survival (all patients).
| Characteristics | Univariate analysis of PFS | Multivariate analysis of PFS | |||
|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | ||
| Age (yr) | ≤50 | 1 | 1 | ||
| >50 | 0.55 (0.37–0.83) | 0.006* | 0.76 (0.48–1.20) | NS | |
| Treatment | RT | 1 | 1 | ||
| CCRT | 0.97 (0.67–1.40) | NS | 0.53 (0.34–0.82) | 0.004* | |
| FIGO stage | IIB–IIIA | 1 | 1 | ||
| IIIB–IVA | 1.73 (1.19–2.55) | 0.004* | 1.49 (1.00–2.26) | 0.052 | |
| PLN meta | Negative | 1 | 1 | ||
| Positive | 1.46 (0.99–2.12) | 0.054 | 1.21 (0.79–1.83) | NS | |
| Tumor size (mm) | ≤40 | 1 | 1 | ||
| >40 | 2.24 (1.42–3.73) | <0.001* | 1.43 (0.87–2.46) | NS | |
| Histology | SCC | 1 | 1 | ||
| AC/ASC | 2.20 (1.25–3.63) | 0.008* | 1.94 (1.07–3.35) | 0.031* | |
| Duration of RT (day) | ≤55 | 1 | 1 | ||
| >55 | 1.17 (0.59–2.08) | NS | 1.00 (0.50–1.81) | NS | |
| Pretreat Hb (g/dL) | <11.0 | 1 | 1 | ||
| ≥11.0 | 0.50 (0.35–0.73) | <0.001* | 0.78 (0.52–1.21) | NS | |
| Response to treatment | CR | 1 | 1 | ||
| Non-CR | 8.47 (5.29–13.20) | <0.001* | 7.57 (4.29–13.30) | <0.001* | |
AC, adenocarcinoma; ASC, adenosquamous carcinoma; CCRT, concurrent chemoradiotherapy; CI, confidence interval; CR, complete response; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; NS, not significant; PFS, progression-free survival; PLN, popliteal lymph node; RT, radiotherapy; SCC, squamous cell carcinoma.
*p-value is less than 0.05.